Cover Image
市場調查報告書

血友病全球市場:產業分析與未來展望

Global Hemophilia Market: Industry Analysis & Outlook 2017-2021

出版商 Koncept Analytics 商品編碼 246749
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
血友病全球市場:產業分析與未來展望 Global Hemophilia Market: Industry Analysis & Outlook 2017-2021
出版日期: 2017年03月27日 內容資訊: 英文 86 Pages
簡介

本報告針對世界血友病治療藥物市場分析、提供疾病概要與市場基本構造、市場規模動向預測 (患者數/金額基準、過去、未來5年)、種類分類 (血友病A/B)、治療等級分類、重症程度分類與地區分類詳細動向、主要市場促進、阻礙因素、市場競爭、資本募集狀況、主要企業檔案。

第1章 市場概要

  • 血友病
  • 血友病種類
  • 徵兆、症狀
  • 診斷/治療法

第2章 世界市場分析

  • 市場規模 (金額基準)
  • 市場規模預測 (金額基準)
  • 治療等級分類市場規模 (金額基準)
    • 傳統型因素市場規模 (預測值、金額基準)
  • 種類分類市場規模
    • 血友病A市場規模 (預測值、金額基準)
    • 血友病A市場規模:治療等級分類 (預測值)
    • 血友病A市場規模:重症度分類
    • 血友病□抑制劑市場規模 (預測值、金額基準)
    • 血友病B市場規模 (預測值、金額基準)
    • 血友病B市場規模:治療等級分類 (預測值)
    • 血友病B市場規模:重症度分類

第3章 地區市場分析

  • 美國市場
    • 市場規模 (金額基準)
    • 市場規模預測 (金額基準)
    • 市場規模:種類分類
    • 血友病A市場規模預測 (金額基準)
    • 血友病A患者數預測 (已治療患者數)
    • 血友病A患者數預測 (兒童患者數)
    • 血友病A患者數預測 (成人患者數)
    • 血友病B市場規模預測 (金額基準)
    • 血友病B患者數預測 (已治療患者)
  • 歐洲市場
    • 患者數預測
    • 血友病A患者數預測
    • 血友病B患者數預測

第4章 市場動態

  • 成長促進要因
    • 對預防治療的關心增加
    • 第VIII因素市場成長
    • 診療率上昇
    • 醫療費用增加
  • 主要動向
    • 新型血友病治療藥物開發
    • 皮下投藥
    • 基因置換型第VIII、第IX因子製劑需求增加
    • 基因療法受歡迎
  • 課題
    • 高額治療成本
    • 變更為新治療方法的抵抗感

第5章 競爭環境

  • 世界血友病市場
    • 市場收益額與時價總額比較
  • 世界血友病A市場
    • 市場佔有率
    • 第VIII因素製品市場佔有率
    • 第VIII因素基因療法市場佔有率預測
  • 世界血友病B市場
    • 市場佔有率
    • 第IX因素製品市場佔有率
    • 第IX因素基因療法市場佔有率預測

第6章 企業檔案

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes abnormal bleeding with poor clotting. It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors.

Treatment for hemophilia is done via replacement therapy, prophylactic therapy, on-demand therapy, gene therapy and many others. Gene therapy is being regarded as an attractive option for treatment of hemophilia. By the year 2030, the pharmaceutical companies are expected to launch their gene therapy treatment for hemophilia, and this might affect the market dynamics at large.

The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, subcutaneous dosing and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumer's reluctance in switching to new therapy options.

The report offers an in-depth analysis of the global hemophilia market. It also covers the global as well as regional aspect of the market. The top notch players in the market exhibit a very close competition. The report profiles Pfizer Inc., Bayer Group, Shire PLC, and Novo Nordisk.

Table of Contents

1. Market Overview

  • 1.1 Hemophilia
  • 1.2 Types of Hemophilia
  • 1.3 Signs & Symptoms
  • 1.4 Diagnosis & Treatment

2. Global Market Analysis

  • 2.1 Global Hemophilia Market by Value
  • 2.2 Global Hemophilia Market Forecast by Value
  • 2.3 Global Hemophilia Market by Therapeutic Class
    • 2.3.1 Global Hemophilia Traditional Factors Market Forecast by Value
  • 2.4 Global Hemophilia Market by Type
    • 2.4.1 Global Hemophilia A Market Forecast by Value
    • 2.4.2 Global Hemophilia A Market Forecast by Therapeutic Class
    • 2.4.3 Global Hemophilia A Market by Severity
    • 2.4.4 Global Hemophilia with Inhibitors Market Forecast by Value
    • 2.4.5 Global Hemophilia B Market Forecast by Value
    • 2.4.6 Global Hemophilia B Market Forecast by Therapeutic Class
    • 2.4.7 Global Hemophilia B Market by Severity

3. Regional Market Analysis

  • 3.1 The US
    • 3.1.1 The US Hemophilia Market by Value
    • 3.1.2 The US Hemophilia Market Forecast by Value
    • 3.1.3 The US Hemophilia Market by Type
    • 3.1.4 The US Hemophilia A Market Forecast by Value
    • 3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
    • 3.1.6 The US Hemophilia A Market-Pediatric Patients Volume Forecast
    • 3.1.7 The US Hemophilia A Market- Adult Patients Volume Forecast
    • 3.1.8 The US Hemophilia B Market Forecast by Value
    • 3.1.9 The US Hemophilia B Market-Treated Patient Volume Forecast
  • 3.2 Europe
    • 3.2.1 Europe's Hemophilia Market- Patient Volume Forecast
    • 3.2.2 Europe's Hemophilia A Market- Patient Volume Forecast
    • 3.2.3 Europe's Hemophilia B Market- Patient Volume Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Increased Focus on Prophylactic Treatment
    • 4.1.2 Growing Market for FVIII
    • 4.1.3 Increasing Diagnosis Rate
    • 4.1.4 Increasing Healthcare Expenditure
  • 4.2 Key Trends
    • 4.2.1 Development of Novel Hemophilia Treatments
    • 4.2.2 Subcutaneous Dosing
    • 4.2.3 Increasing Demand for Recombinant Versions of Factor VIII & FIX Drugs
    • 4.2.4 Popularity of Gene Therapy
  • 4.3 Challenges
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Reluctance to Switch to New Therapies

5. Competitive Landscape

  • 5.1 Global Hemophilia Market
    • 5.1.1 Revenue and Market Cap Comparison
  • 5.2 Global Hemophilia A Market
    • 5.2.1 Market Share
    • 5.2.2 Factor VIII Products Market Share
    • 5.2.3 Factor VIII Gene Therapy Market Share Forecast
  • 5.3 Global Hemophilia B Market
    • 5.3.1 Market Share
    • 5.3.2 Factor IX Products Market Share Forecast
    • 5.3.3 Factor IX Gene Therapy Market Share Forecast

6. Company Profiles

  • 6.1 Pfizer Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Bayer Group
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Shire PLC
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Novo Nordisk
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Depiction of Inheritance of Hemophilia
  • Types of Hemophilia
  • Global Hemophilia Market by Value (2012-2016)
  • Global Hemophilia Market Forecast by Value (2017-2021)
  • Global Hemophilia Market by Therapeutic Class (2016- 2030)
  • Global Hemophilia Traditional Factors Market Forecast by Value (2016-2021)
  • Global Hemophilia Market by Type (2016)
  • Global Hemophilia A Market Forecast by Value (2016-2021)
  • Global Hemophilia A Market Forecast by Therapeutic Class (2016- 2030)
  • Global Hemophilia A market by Severity (2016)
  • Global Hemophilia with Inhibitors Market Forecast by Value (2016-2021)
  • Global Hemophilia B Market Forecast by Value (2016-2021)
  • Global Hemophilia B Market Forecast by Therapeutic Class (2016- 2030)
  • Global Hemophilia B Market by Severity (2016)
  • The US Hemophilia Market by Value (2012-2016)
  • The US Hemophilia Market Forecast by Value (2017-2021)
  • The US Hemophilia Market by Type (2016)
  • The US Hemophilia A Market Forecast by Value (2016-2021)
  • The US Hemophilia A Market-Treated Patient Volume Forecast (2016-2021)
  • The US Hemophilia A Market-Pediatric Patients Volume Forecast (2016-2021)
  • The US Hemophilia A Market- Adult Patients Volume Forecast (2016-2021)
  • The US Hemophilia B Market Forecast by Value (2016-2021)
  • The US Hemophilia B Market-Treated Patient Volume Forecast (2016-2021)
  • Europe's Hemophilia Market- Patient Volume Forecast (2016-2021)
  • Europe's Hemophilia A Market- Patient Volume Forecast (2016-2021)
  • Europe's Hemophilia B Market- Patient Volume Forecast (2016-2021)
  • Market Share of Hemophilia A Patients on Prophylaxis in the US (2014-2016)
  • Market Share of Hemophilia B Patients on Prophylaxis in the US (2014-2016)
  • Global Hemophilia A Factor VIII Products Market by Value (2016-2021)
  • Global Identified Hemophilia Patients Volume (2005-2016)
  • Global Healthcare Expenditure (2012-2016)
  • Global Hemophilia A Market Share by Company (2016)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2021/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2016)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2021/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • Pfizer Inc.'s Revenue Share by Major Business Segment (2016)
  • Pfizer Inc.'s Revenue and Net Income (2012-2016)
  • Pfizer Inc. R&D Expenses (2015-2016)
  • Bayer Group's Net Sales Share by Business Segments (2016)
  • Bayer Group's Net Sales and Net Income (2012-2016)
  • Shire PLC's Revenue Share by Franchise (2016)
  • Shire PLC's Revenue and Net Income (2012-2016)
  • Novo Nordisk's Net Sales Share by Business Segments (2016)
  • Novo Nordisk's Net Sales and Net Profit (2012-2016)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Development of New Novel Hemophilia Treatments (2016)
  • Developed and Upcoming Long Acting Factor VIII Drugs
  • Factor IX Products in Development
  • Upcoming Hemophilia Gene Therapy Candidates (2016-2030)
  • Global Hemophilia Revenue & Market Cap Comparison by Key Players (2016)
  • Major Business Segments of Pfizer Inc.
  • Major Products Developed by Pfizer Inc. (Since November 1, 2016)
  • Bayer Group's R&D Expenses by Business Segments (2016)
  • Shire PLC's Major Product Approvals & Launches (2016)
  • Shire PLC's Major Product Pipeline (2016)
  • Novo Nordisk's Research and Development (2014-2016)
  • Novo Nordisk's Product Pipeline (2016)
Back to Top